LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

LLY

765.61

+0.24%↑

JNJ

175.55

-0.76%↓

ABBV

220.25

-0.19%↓

UNH

340.14

-0.01%↓

AZN

76.65

-1.34%↓

Search

Fulgent Genetics Inc

Отворен

СекторЗдравеопазване

22.4 1.17

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

21.56

Максимум

22.53

Ключови измерители

By Trading Economics

Приходи

-7.4M

-19M

Продажби

8.3M

82M

Марж на печалбата

-23.539

Служители

1,313

EBITDA

-3.5M

-15M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+15.45% upside

Дивиденти

By Dow Jones

Следващи печалби

7.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

124M

673M

Предишно отваряне

21.23

Предишно затваряне

22.4

Настроения в новините

By Acuity

50%

50%

167 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Fulgent Genetics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.09.2025 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17.09.2025 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17.09.2025 г., 21:59 ч. UTC

Печалби

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17.09.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

17.09.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17.09.2025 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17.09.2025 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17.09.2025 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17.09.2025 г., 22:19 ч. UTC

Придобивния, сливания и поглъщания

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17.09.2025 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17.09.2025 г., 21:00 ч. UTC

Печалби

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

17.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

17.09.2025 г., 19:59 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.09.2025 г., 19:59 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17.09.2025 г., 19:07 ч. UTC

Пазарно говорене

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17.09.2025 г., 18:43 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17.09.2025 г., 18:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17.09.2025 г., 18:20 ч. UTC

Пазарно говорене

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17.09.2025 г., 18:18 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.09.2025 г., 18:18 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17.09.2025 г., 18:14 ч. UTC

Пазарно говорене

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17.09.2025 г., 17:59 ч. UTC

Пазарно говорене

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17.09.2025 г., 17:15 ч. UTC

Придобивния, сливания и поглъщания

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17.09.2025 г., 17:06 ч. UTC

Придобивния, сливания и поглъщания

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17.09.2025 г., 16:51 ч. UTC

Печалби

Correct: Exor 1H Net Loss -EUR624M

17.09.2025 г., 16:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

17.09.2025 г., 16:34 ч. UTC

Пазарно говорене

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17.09.2025 г., 16:25 ч. UTC

Печалби

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17.09.2025 г., 16:23 ч. UTC

Печалби

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Сравнение с други в отрасъла

Ценова промяна

Fulgent Genetics Inc Прогноза

Ценова цел

By TipRanks

15.45% нагоре

12-месечна прогноза

Среден 25.33 USD  15.45%

Висок 30 USD

Нисък 21 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Fulgent Genetics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

3 ratings

2

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

17.32 / 19.04Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

167 / 371 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat